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Comparisons of immunoglobulin G (IgG) subclass responses to the major polymorphic region and to a
conserved region of MSP-1 in three cohorts of African villagers exposed to Plasmodium falciparum revealed that
responses to Block 2 are predominantly IgG3 whereas antibodies to MSP-119 are mainly IgG1. The striking
dominance of IgG3 to Block 2 may explain the short duration of this response and also the requirement for
continuous stimulation by malaria infection to maintain clinical immunity.
Effective human immunity to blood forms of Plasmodium
falciparum involves the acquisition of anti-parasite antibodies
(Abs) of the cytophilic immunoglobulin G (IgG) subclasses 1
and 3, targeted at surface antigens of the invasive extracellular
merozoite stage of P. falciparum (3, 4). The absence of para-
site-specific IgG3 Abs can be associated with poor clinical
prognosis of malaria (32). Although IgG1 and/or IgG3 Abs
specific for merozoite and/or schizont antigens are relevant to
clinical protection, the identity of the target antigens remains
to be elucidated.
Merozoite surface protein 1 (MSP-1) is the precursor of
most merozoite surface antigens (20, 27). The MSP-1 gene of
P. falciparum encodes conserved, dimorphic, and polymor-
phic regions of the protein (28, 35). There are two major
families of MSP-1, based on the dimorphic sequences (35).
Polymorphism in the Block 2 region is more extensive, but all
Block 2 sequences belong to one or another of only three main
types represented by variants originally described in the K1,
MAD20, and RO33 isolates (9, 28, 35).
Abs to the conserved MSP-119 region, found in most malar-
ia-exposed individuals (7, 33), have been correlated with pro-
tection from clinical symptoms of malaria in some but not all
studies (1, 11, 30). Abs to polymorphic and/or dimorphic se-
quences located outside MSP-119 may also play a role in im-
munity (7, 17, 29). Recently, a novel approach combining pop-
ulation genetics with an immunoepidemiological prospective
cohort study has identified Block 2 as a major target of human
immunity to clinical malaria (10).
Antibody isotype distributions of IgG responses to Block 2
and MSP-119 regions were compared in individuals from areas
with different levels of malaria transmission. Plasma samples
were selected for IgG subclass analysis from larger sets of
samples on the basis of a single criterion, the presence of
substantial amounts of Block 2-specific total IgG (optical den-
sity [OD] . 0.9 at a 1/500 dilution). Plasma samples were from
three cohorts of donors. In the village of Daraweesh, Sudan, 28
donors (age 5 to 35 years) were from a cohort of 52, with
plasma samples taken during or following documented malaria
infections. In Koka, eastern Sudan, 29 donors (age 3 to 65
years) were from a cohort of 70 individuals who were blood
film positive for P. falciparum. From 200 people surveyed in
the area around Kilifi, Kenya, a month after malaria transmis-
sion peak, 29 donors (age 0.5 to 76 years) were selected; 15 of
these were blood film positive and 14 tested blood film nega-
tive for P. falciparum. Malaria epidemiology at these sites has
been described elsewhere (5, 14, 34). All blood samples were
obtained after informed consent of donors or their parents.
Nine different recombinant glutathione S-transferase fusion
proteins of MSP-1 Block 2, representative of all three known
Block 2 types, were used (7, 8). Sequences of all these proteins
have been published (7, 8). MSP-119 fusion protein was as
described previously (6). Plasma samples were tested by en-
zyme-linked immunosorbent assay (ELISA) for total IgG and
all IgG subclasses able to recognize the 10 different recombi-
nant MSP-1 antigens as described elsewhere (7, 8, 16). The
antigens were coated separately onto parallel columns of wells
on 96-well plates (Immunlon 4; Dynex Technologies) at 50 ng
per well. Each plasma sample, diluted 1:500, was added to two
rows of antigen-coated wells on a plate and held at 4°C over-
night. Thus, any one plasma sample was tested in duplicate
against all different antigens on the same plate at the same
time. Identical sets of antigen-coated plates were prepared for
the determination of total IgG, IgG1, IgG2, IgG3, or IgG4 in
assays performed with any one plasma sample in parallel on
the same day. Plasma samples from any one location were all
tested on the same day. Next, wells were incubated for 3 h with
100 ml per well of horseradish peroxidase (HRP)-conjugated
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polyclonal sheep Abs specific for human IgG1 (1:1,000), IgG2
(1:1,000), IgG3 (1:6,000), or IgG4 (1:3,000) (The Binding Site,
Birmingham, United Kingdom) or HRP-conjugated polyclonal
rabbit Abs against human total IgG specific for gamma chains
(1:5,000; Dako). The wells were washed with 100 ml of sub-
strate (0.1 mg of o-phenylenediamine per ml 0.012% H2O2) in
development buffer before being incubated (7, 8). The reac-
tions were stopped by addition of 20 ml of 2 M H2SO4, and the
OD492 was measured. For each plasma sample, IgG subclass,
and antigen combination, corrected OD492 values were calcu-
lated by subtracting a mean OD value of two wells containing
the control GST protein alone from a mean OD value of
duplicates obtained with each combination.
MSP-1-specific IgG subclass concentrations were estimated
by an indirect standardization method (38). Purified human
myeloma proteins IgG1, IgG2, IgG3, and IgG4 were coated on
ELISA plates at threefold dilutions from 10 to 0.00457 mg
ml21. HRP-conjugated Abs to each IgG subclass (at the same
dilutions as used for plasma samples) were reacted with the
myeloma proteins and developed as above. Standard curves
were produced for each IgG subclass in each experiment. The
amounts of anti-MSP-1 Abs in each plasma sample were esti-
mated for each antigen-IgG subclass combination by convert-
ing OD492 readings to Ab concentrations in micrograms per
milliliter by interpolation from the standard curves using poly-
nomial regression. The concentrations of Block 2- and of MSP-
119-specific IgG subclass Abs were determined and compared
in one experiment for all individuals in each of the cohorts
tested.
The results are summarized in Figure 1. IgG1 and IgG3
levels are shown for Block 2- or MSP-119-specific Abs in sep-
arate panels. Individuals had IgG subclasses recognizing Block
2 antigens in a type-specific manner, i.e., most samples con-
tained IgG specific for only one of the three Block 2 types (data
not shown). The levels of Block 2-specific IgG1 and IgG3 from
any one individual are shown as a single data point represent-
ing the maximum detected with any one of the antigens used.
Results for all three Block 2 types were similar and are com-
bined in Fig. 1 for simplicity. In each donor cohort, the pre-
dominant response to Block 2 was of the IgG3 subclass, with a
few individuals having both IgG3 and IgG1 (Fig. 1). In con-
trast, in the same donors, the predominant response to the
MSP-119 region was of the IgG1 subclass, with some samples
also containing IgG3. No IgG2 or IgG4 to any Block 2 type or
to MSP-119 were detected in any donor (data not shown). Each
cohort illustrated the same striking bias toward IgG3 responses
to Block 2 and towards IgG1 responses to MSP-119. These
distinct subclass biases of the responses to different regions of
MSP-1 were statistically significant in all three cohorts of do-
nors when analyzed by the two-tailed Wilcoxon matched-pairs
ranked sign test. IgG3 was the predominant subclass against
Block 2 at all three sites (z 5 23.319, P , 0.0001 [Kilifi]; z 5
22.5048, P , 0.0124 [Daraweesh]; and z 5 24.552, P ,
0.00006 [Koka]). In contrast, IgG1 was the predominant Ab
subclass directed against MSP-119 (z 5 22.9948, P , 0.0028
[Kilifi]; z 5 23.2335, P , 0.0014 [Daraweesh]; z 5 23.254, P ,
0.0014 [Koka]).
Plasma samples from individuals in Daraweesh were from a
longitudinal study of immune responses to malaria conducted
since 1990 (7, 18). Therefore, we tested whether changes in
IgG subclass response profiles occurred in individuals over 3 to
4 years. Longitudinal series of plasma samples from eight in-
dividuals (5 to 11 samples each) were assessed for the IgG
subclass composition of Abs to Block 2 and MSP-119 in suc-
cessive transmission seasons. Seven of the individuals consis-
tently produced IgG3 to Block 2 and, equally consistently,
IgG1 to MSP-119 in response to their clinical malaria infec-
tions. IgG subclass profiles of individuals A3, X7, and F11 are
shown as examples in Fig. 2A to C. Among the eight individ-
uals tested longitudinally, the one notable exception to the
general pattern was the response of individual 2J8 to MSP-119,
which shifted from the usual IgG1 subclass in 1993 to the IgG3
subclass following a clinical infection in 1994 (Fig. 2D). The
anti-Block 2 response of this individual was IgG3, as usual.
This study presents the first direct evidence for strikingly
distinct subclass preferences of Ab responses to two different
regions of one protein, the Block 2 and the MSP-119 regions of
MSP-1. It poses general questions about the regulation of
human isotype responses and specific questions about the con-
sequences of such responses in malaria. Strong IgG subclass
biases to either IgG1 or IgG3 are a feature of human responses
to different protein antigens of P. falciparum merozoites. Sim-
ilar to the IgG3 bias of responses to Block 2, IgG3 is the main
subclass in response to another merozoite surface protein
(MSP-2) in Gambians (36) and in Solomon Islanders (31).
Similar to the IgG1 bias to MSP-119 (13), responses to RAP-1,
another antigen of P. falciparum merozoites, are also biased to
the IgG1 subclass (16).
Protein antigens of most bacteria and viruses induce both
IgG1 and IgG3 antibodies, with IgG1 generally being the dom-
inant antiviral subclass (15, 19, 25). Virus-specific IgG3 corre-
lates with current infection by nonlatent viruses and is nor-
mally a short-lived response (26). Persistence of IgG3 is usually
seen only in asymptomatic latent viral infections, indicating
that the presence of viral Ag is required for maintenance of the
IgG3 responses (24). Like these antiviral responses, the gen-
eralized bias to IgG3 of Block 2-specific responses could be
because most of the donors tested in this study were infected at
the time of or shortly before plasma sample collection. How-
ever, an IgG3 bias would also be expected in the responses of
these donors to MSP-119, but this was not observed. Thus,
there must be other explanations for the differential subclass
bias of responses to different regions of MSP-1.
Responses to multimeric antigens can be distinctly different
from responses to less organized, soluble proteins. Repetitive-
ness of antigen structures on surfaces of cells or viral particles
is sensed by the degree of cross-linking of surface Ig on B cells,
which are thought to recognize antigen organization as a gen-
eral marker of foreignness (2). Epitopes from viral proteins
can elicit rapid T-cell-independent Ab responses, if expressed
as part of a surface protein on recombinant bacteria, whereas
the same epitopes elicit delayed, T-cell-dependent Ab re-
sponses when expressed as soluble, internal antigens (23).
MSP-119, believed to be attached to the merozoite surface,
could be recognized as a repetitively arranged surface antigen
on the relatively large merozoite (1 mm). In contrast, Block 2
of MSP-1 is located on the MSP-183 fragment, a component of
a soluble protein complex shed from the surface of the para-
site. The uptake and processing by antigen-presenting cells of
Block 2 and MSP-119 may therefore be different and is likely to
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influence the type of antibody produced. MSP-119 on merozo-
ites probably would be phagocytosed for presentation by mac-
rophages. In comparison, the soluble Block 2 is likely to be
taken up by different antigen-presenting cells, e.g., follicular
dendritic cells.
The significance of the IgG3 bias in the response to the
polymorphic Block 2 of MSP-1 in malaria immunity is not yet
known. Merozoite-specific antibodies of the IgG1 and IgG3
subclasses can trigger the release of soluble anti-parasite me-
diators from monocytes in vitro (12), but whether there are
FIG. 1. Comparisons of IgG subclass levels to Block 2 and MSP-119 regions. Each point shows Ab levels (in micrograms per milliliter) of IgG1
and IgG3 in an undiluted plasma sample from one individual. Ab levels specific for the Block 2 and MSP-119 regions of MSP-1 in the same sets
of plasma samples are plotted on adjacent graphs. Results are shown separately for cohorts of donors from Kilifi (Kenya), Daraweesh (Sudan),
and Koka (Sudan).
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differences in the effectiveness of these two subclasses is not
known. Soluble immune complexes of antigen and specific
IgG3 interact differently with immune effector cells than do
complexes formed by other IgG subclasses (22, 37). IgG3-
containing complexes could mediate beneficial effects, such as
Ab-dependent cellular cytotoxicity and phagocytosis of the
parasite, or pathological inflammation. Kelly proposed the hy-
pothesis that in a population with a high frequency of a mutant
allotype of IgG3, a chronic presence of circulating immune
complexes of unknown malaria antigens with IgG3 contributes
to hyperreactive malarious splenomegaly, a chronic complica-
tion of malaria associated with up to 60% mortality (21). How-
ever, anti-Block 2 Abs, shown here to be mostly IgG3, are
strongly associated with protection against clinical malaria,
with protective efficacy in the range of 22 to 46% for type-
specific Abs against types of Block 2 that are most prevalent in
natural populations of P. falciparum (10). Further work is nec-
essary to elucidate the protective and/or pathological potential
of different IgG subclass responses against distinct portions of
P. falciparum MSP-1.
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